Entellus Medical, Inc. (NASDAQ:ENTL) VP Karen E. Peterson sold 650 shares of Entellus Medical stock in a transaction on Monday, October 9th. The shares were sold at an average price of $20.17, for a total value of $13,110.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Entellus Medical, Inc. (NASDAQ:ENTL) traded up 1.39% during midday trading on Wednesday, hitting $19.75. The stock had a trading volume of 76,628 shares. Entellus Medical, Inc. has a 1-year low of $11.47 and a 1-year high of $22.63. The stock’s market cap is $501.08 million. The company has a 50-day moving average of $18.18 and a 200-day moving average of $18.18.
Entellus Medical (NASDAQ:ENTL) last announced its quarterly earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.03). Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The firm had revenue of $22.10 million during the quarter, compared to the consensus estimate of $21.87 million. During the same quarter in the previous year, the company posted ($0.27) earnings per share. The firm’s revenue was up 18.0% on a year-over-year basis. Equities research analysts forecast that Entellus Medical, Inc. will post ($1.61) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.com-unik.info/2017/10/11/entellus-medical-inc-entl-vp-sells-13110-50-in-stock.html.
Several research firms have recently commented on ENTL. Zacks Investment Research raised Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 target price for the company in a research note on Monday. BidaskClub raised Entellus Medical from a “buy” rating to a “strong-buy” rating in a research note on Friday, July 14th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $21.00 target price on shares of Entellus Medical in a research note on Tuesday, August 22nd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $22.00.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
What are top analysts saying about Entellus Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Entellus Medical Inc. and related companies.